Literature DB >> 22205702

Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.

Hua Xiong1, Jie Hong, Wan Du, Yan-wei Lin, Lin-lin Ren, Ying-chao Wang, Wen-yu Su, Ji-lin Wang, Yun Cui, Zhen-hua Wang, Jing-Yuan Fang.   

Abstract

The progression of colorectal carcinoma (CRC) to invasive and metastatic disease may involve localized occurrences of epithelial-mesenchymal transition (EMT). However, mechanisms of the EMT process in CRC progression are not fully understood. We previously showed that knockdown of signal transducer and activator of transcription 3 (STAT3) up-regulated E-cadherin (a key component in EMT progression) in CRC. In this study, we examined the roles of STAT3 in CRC EMT and ZEB1, an EMT inducer, in STAT3-induced down-regulation of E-cadherin. Knockdown of STAT3 significantly increased E-cadherin and decreased N-cadherin and vimentin expressions in highly invasive LoVo CRC cells. Meanwhile, overexpression of STAT3 significantly reduced E-cadherin and enhanced N-cadherin and vimentin expressions in weakly invasive SW1116 CRC cells. Activation of STAT3 significantly increased CRC cell invasiveness and resistance to apoptosis. Knockdown of STAT3 dramatically enhanced chemosensitivity of CRC cells to fluorouracil. STAT3 regulated ZEB1 expression in CRC cells, and the STAT3-induced decrease in E-cadherin and cell invasion depended on activation of ZEB1 in CRC cells. Additionally, pSTAT3(Tyr-705) and ZEB1 expressions were significantly correlated with TNM (tumor, lymph node, and metastasis stages) (p < 0.01). In conclusion, STAT3 may directly mediate EMT progression and regulate ZEB1 expression in CRC. ZEB1 may participate in STAT3-induced cell invasion and E-cadherin down-regulation in CRC cells. The expressions of pSTAT3(Tyr-705) and ZEB1 may be positively associated with CRC metastasis. Our data may provide potential targets to prevent and/or treat CRC invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205702      PMCID: PMC3285352          DOI: 10.1074/jbc.M111.295964

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells.

Authors:  Charisa L Cottonham; Satoshi Kaneko; Lan Xu
Journal:  J Biol Chem       Date:  2010-09-07       Impact factor: 5.157

2.  Integration of a Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation.

Authors:  Luis Luna-Zurita; Belén Prados; Joaquim Grego-Bessa; Guillermo Luxán; Gonzalo del Monte; Alberto Benguría; Ralf H Adams; José María Pérez-Pomares; José Luis de la Pompa
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

3.  TAF4b and Jun/activating protein-1 collaborate to regulate the expression of integrin alpha6 and cancer cell migration properties.

Authors:  Margarita Kalogeropoulou; Angeliki Voulgari; Vassiliki Kostourou; Raphael Sandaltzopoulos; Rivka Dikstein; Irwin Davidson; Laszlo Tora; Alexander Pintzas
Journal:  Mol Cancer Res       Date:  2010-03-30       Impact factor: 5.852

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

5.  Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition.

Authors:  Dayong Ren; Yasuhiro Minami; Michiru Nishita
Journal:  Genes Cells       Date:  2011-03       Impact factor: 1.891

6.  FOXQ1 regulates epithelial-mesenchymal transition in human cancers.

Authors:  Yuanyuan Qiao; Xia Jiang; Shuet Theng Lee; R K Murthy Karuturi; Shing Chuan Hooi; Qiang Yu
Journal:  Cancer Res       Date:  2011-02-23       Impact factor: 12.701

7.  Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes.

Authors:  Yue-Lei Chen; Jing Lv; Xiao-Lei Ye; Ming-Yu Sun; Qin Xu; Cheng-Hai Liu; Li-Hua Min; Hui-Ping Li; Ping Liu; Xiaoyan Ding
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

8.  Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts.

Authors:  Y Morita; T Naka; Y Kawazoe; M Fujimoto; M Narazaki; R Nakagawa; H Fukuyama; S Nagata; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

9.  Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.

Authors:  Y Gan; C Shi; L Inge; M Hibner; J Balducci; Y Huang
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

Review 10.  Cadherins as novel targets for anti-cancer therapy.

Authors:  Orest W Blaschuk; Emmanuelle Devemy
Journal:  Eur J Pharmacol       Date:  2009-10-16       Impact factor: 4.432

View more
  122 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

2.  Notch-1-mediated esophageal carcinoma EC-9706 cell invasion and metastasis by inducing epithelial-mesenchymal transition through Snail.

Authors:  Tao Wang; Xiaoyan Xuan; Linping Pian; Ping Gao; Hong Hu; Yuling Zheng; Wenqiao Zang; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2014-02

3.  Identification of differentially expressed genes and their upstream regulators in colorectal cancer.

Authors:  H Y Liu; C J Zhang
Journal:  Cancer Gene Ther       Date:  2017-04-14       Impact factor: 5.987

4.  Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model.

Authors:  Jeong Won Park; Li Zhao; Mark C Willingham; Sheue-Yann Cheng
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

5.  HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.

Authors:  Debarati Banik; Satish Noonepalle; Melissa Hadley; Erica Palmer; Maria Gracia-Hernandez; Christian Zevallos-Delgado; Namratta Manhas; Hayk Simonyan; Colin N Young; Anastas Popratiloff; Katherine B Chiappinelli; Rohan Fernandes; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Cancer Res       Date:  2020-06-30       Impact factor: 12.701

6.  Epithelial-mesenchymal transition - activating transcription factors - multifunctional regulators in cancer.

Authors:  Minal Garg
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

7.  Wnt signaling through Snail1 and Zeb1 regulates bone metastasis in lung cancer.

Authors:  Xinghai Yang; Lei Li; Quan Huang; Wei Xu; Xiaopan Cai; Jishen Zhang; Wangjun Yan; Dianwen Song; Tielong Liu; Wang Zhou; Zhenxi Li; Cheng Yang; Yongyan Dang; Jianru Xiao
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

8.  miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.

Authors:  Fa-Yong Hu; Xiao-Nian Cao; Qin-Zi Xu; Yu Deng; Sen-Yan Lai; Jing Ma; Jun-Bo Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

9.  Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Authors:  Dimiter B Avtanski; Arumugam Nagalingam; Michael Y Bonner; Jack L Arbiser; Neeraj K Saxena; Dipali Sharma
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

Review 10.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.